Clinical biology and potential use of thrombopoietin

Russell Basser MBBS

Before the cytokine era, with no active means of manipulating blood counts, myelosuppression was managed conservatively. Patients were given red blood cell transfusions for anemia, antibiotics for neutropenic fever, and platelet transfusions for prophylaxis and treatment of bleeding. The clinical development of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor challenged this conservative approach. The administration of these agents after chemotherapy was found to reduce the period of neutropenia, the frequency of fever and the duration of inpatient treatment, and to enhance the ability to maintain dose intensity (1). Furthermore, myeloid growth factors have been found to elevate neutrophil levels successfully in other causes of severe neutropenia, thereby reducing the frequency of infection (2-5).

Biologie clinique et usage potentiel de la thrombopoïétine

RÉSUMÉ : La découverte des facteurs de croissance plaquettaire ont fait naître l’espoir de disposer éventuellement d’une méthode clinique efficace pour contrer la thrombocytopénie. Les premières cytokines découvertes étaient de nature pléiotropique et la stimulation de la production plaquettaire était en général modeste. Par contre, l’un des ces agents, l’interleukine-11, s’est révélé apte à réduire l’incidence de la thrombocytopénie grave chez les patients traités par chimiothérapie intensive et vient de recevoir l’approbation de la FDA pour cette indication. Les premiers essais cliniques sur la thrombopoïétine (TPO), principal régulateur de la mégacaryocytopoïèse et de la thrombocytopoïèse, et ses analogues ont révélé que ces agents sont de puissants stimulants de la thrombopoïèse et donnent lieu à peu de réactions indésirables. Ils ont également prouvé leur capacité de stimuler la remontée plaquettaire après la chimiothérapie, mais les résultats des premiers essais à avoir tenté de mesurer leur aptitude à prévenir la thrombocytopénie grave associée à la leucémie et à la transplantation de moelle osseuse ont été décevants. De plus, on a noté que l’administration sous-cutanée de l’un de ces agents, le facteur de croissance et de développement des mégacaryocytes, donnait lieu à la formation d’anticorps qui neutralisaient la TPO native et causaient la thrombocytopénie. Les facteurs de croissance plaquettaire sont sans contredit des agents thérapeutiques prometteurs, mais il reste plusieurs obstacles à surmonter avant qu’on puisse les utiliser d’emblée en clinique.

Key Words: Clinical review; Megakaryocyte growth and development factor; Thrombopoietin

This mini-review was prepared from a presentation made at the World Congress of Gastroenterology, Vienna, Austria, September 6 to 11, 1998 Department of Haematology and Medical Oncology, Royal Melbourne Hospital and Western Hospital, Victoria, Australia. Correspondence and reprints: Russell Basser, Departments of Haematology and Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria 3050, Australia. Telephone +61-3-9342-7695, fax +61-3-9347-7508, e-mail russell.basser@mh.org.au

Received for publication February 11, 1999. Accepted February 25, 1999
The search for thrombopoietin

An adequate number of circulating blood platelets is vital to maintain hemostasis. The response to a reduction in platelet numbers is mediated through a complex and highly regulated process that involves the interaction of megakaryocytic progenitors, bone marrow stromal cells and cytokines (6). A number of cytokines, including interleukin (IL)-1 (7), IL-6 (8), IL-11 (9) and leukemia inhibitory factor (10), have been found to promote thrombopoiesis at different stages of progenitor cell and megakaryocyte development. However, the pleiotropic activities of these cytokines indicate that control of megakaryocytopoiesis is unlikely to be their primary physiological function.

The term thrombopoietin (TPO) was first coined in 1958, by Kelemen et al (11), to describe a humoral substance that appeared to regulate platelet production. Kelemen et al (11) found that the urine, serum and plasma of animals and patients with severe thrombocytopenia could increase platelet numbers when injected into normal animals (12). However, the search for a single hormonal agent responsible for thrombopoiesis was so difficult that it was thought that it only required a number of different cytokines.

The initial breakthrough in the search for TPO came with the discovery of the murine myeloproliferative oncogene, v-mpl (13). The great serendipity of this finding was realized with the recognition that the cellular homologue of v-mpl, termed c-mpl, encoded the cytoplasmic portion of a membrane protein expressed on hematopoietic cells, predominantly those of megakaryocytic lineage (14,15). A critical observation was that the addition of c-mpl antisense oligonucleotides to cultured CD34+ cells selectively prevented the generation of megakaryocyte colonies (15). The flurry of activity searching for the ligand to c-mpl came to a climax in 1994 with the publication of the sequence of the cDNA (16-21). Mpl ligand has subsequently been shown to be the central physiological regulator of megakaryocytopoiesis and platelet production, and is now referred to in its natural form as TPO (22,23).

Human TPO is a 60 to 70 kDa, glycosylated protein that is primarily produced in the liver and kidneys (16,24). It consists of 332 amino acids, is highly conserved among species and has 23% homology with human erythropoietin (EPO) (25). Recombinant human megakaryocyte growth and development factor (MGDF) is a truncated form of Mpl ligand with identical biological activity in vitro (26-28) and in vivo (29,30). It is homologous with the EPO-like amino-terminus of human TPO (16,27), suggesting that the EPO-like domain contains all the required elements to bind and activate c-mpl. The pegylated form of MGDF is approximately 10 times more potent in vivo than the nonpegylated molecule (31) and was chosen as the agent for clinical use by Amgen Inc (Australia). A full-length glycosylated form of TPO is being developed by Genentech Inc (California). Clinical trials with MGDF and TPO commenced in 1995.

TPO – AT THE CENTRE OF PLATELET PRODUCTION

TPO acts as a megakaryocyte growth and differentiation and/or maturation factor (26,32-37). The pivotal role of the cytokine in platelet production was demonstrated by the marked reduction in platelet levels in c-mpl- (38,39) and TPO-deficient mice (40) to that of 5% to 15% of littermate controls. Because platelet counts in the deficient animals are detectable, it is obvious that other thrombopoietic cytokines such as IL-3, IL-6, IL-11 and stem cell factor play a minor role in platelet production.

Further evidence of the regulatory role of TPO in thrombopoiesis was demonstrated by the finding of an inverse relationship between platelet count and serum TPO in animals and humans (26,41-44). As platelet counts recovered, TPO levels decreased. Interestingly, production of TPO appears to be regulated by platelet mass, rather than at the transcriptional level (45-47), and it is unlikely that the rate of TPO gene expression is altered in response to physiological stimuli (22). Platelet c-mpl has a high affinity for the ligand (48,49), and when bound, the ligand is internalized and degraded (50).

CLINICAL STUDIES WITH TPO

TPO alone: In a phase 1 study in patients with advanced cancer, a dose-dependent increase in platelet counts was observed after the administration of MGDF for up to 10 days (Figure 1), although considerable individual variation was seen in response (51). Patients who received 0.3 and 1.0 μg/kg MGDF had increases in platelet counts ranging from 51% to 584%. Platelet counts peaked between days 12 and 18 inclusive, and they returned to normal between days 22 and 30. The delay between ceasing MGDF and the subse-
quent maximum platelet count varied from two to 12 days. However, an increase in bone marrow megakaryocytes by up to 1.8-fold was observed at doses of 0.03 to 1.0 µg/kg MGDF. The peak count was reached up to seven days after cessation of MGDF, and platelets returned to normal between days 22 and 30. The rise in platelet counts in the lower dose cohorts was considerably less pronounced. No effects were observed on absolute neutrophil count or hematocrit.

These observations were consistent with those of Vadhan-Raj et al (52), who administered a single dose of TPO to patients before chemotherapy. They reported elevated platelet counts of up to 212%, and the kinetics of thrombocytosis were similar to the results of the study by Basser et al (51).

**TPO after chemotherapy:** In an Australian study by Basser et al (53), MGDF 0.3 to 5.0 µg/kg/day was given with filgrastim following moderately myelosuppressive doses of chemotherapy (carboplatin 600 mg/m² and cyclophosphamide 1200 mg/m²). The platelet nadir occurred significantly earlier than in the placebo group, analogous to the effect of G-CSF on neutrophil recovery following chemotherapy (53). However, MGDF did not influence the depth of the platelet nadir but shortened the time to recovery of pretreatment platelet count (median 17 days versus 22 days for the placebo group). In an American study by Fanucchi et al (54), when MGDF was given alone after paclitaxel 175 mg/m² and carboplatin area under the curve (AUC) was 9, the nadir of the platelet count was higher and the time to recovery of baseline platelet count was shorter than that observed with placebo (55). No dose-response to MGDF was observed in this study. While this regimen only produced mild myelosuppression (nadir platelet count in the placebo group of 111×10⁹/L), the same investigators have reported preliminary results of a more intensive regimen in which patients were given the same dose of paclitaxel but with carboplatin AUC of 11 (55). The platelet nadir in the first cycle for the placebo plus MGDF 5 µg/kg group was 21×10⁹/L and 89×10⁹/L, respectively. In addition, the number of patients requiring transfusion during the first two cycles was 64% and 17%, respectively. In another meeting report, MGDF was shown to reduce platelet toxicity and transfusion requirements in patients receiving dose-intensive chemotherapy for non-Hodgkin’s lymphoma (56).

There is one published report on the effects of MGDF in the treatment of acute leukemia (57). No influence on the severity or duration of thrombocytopenia was demonstrated.

**TPO after high-dose chemotherapy:** The only published reports of TPO after high-dose chemotherapy are in abstract form, but these provide an interesting insight into the difficulties that have emerged in the early clinical trials. In one study, 50 patients receiving high-dose chemotherapy and bone marrow support were given either placebo or MGDF, 5 or 10 µg/kg (58). Platelet recovery was improved in the MGDF groups, and was associated with a 34% reduction in the duration of severe thrombocytopenia and an almost 50% reduction in the need for platelet transfusions. In contrast, MGDF did not improve platelet recovery after high-dose chemotherapy and peripheral blood progenitor cell (PBPC) support, when given either after (59), or before and after (60) progenitor transfusion. As mentioned above, the infusion of PBPC has been shown to enhance platelet recovery after high-dose chemotherapy compared with bone marrow, probably because of the greater number of stem cells that can be harvested. It may be that the use of PBPC has already reduced the duration of severe thrombocytopenia to an ‘obligatory’ minimum, and that further reduction with growth factors is not possible.

**PBPC mobilization:** Given the expression of c-mpl on CD34⁺ cells, the observations of progenitor cell mobilization in preclinical models, and the unexpected observations of PBPC mobilization during phase I studies of G-CSF, levels of PBPC were assessed in the early clinical trials of TPO.

In contrast to the lineage-restricted effect of MGDF on mature cells, mobilization of progenitor cells of all lineages occurred. However, there was a preferential increase in blood levels of megakaryocyte progenitor cells compared with myeloid progenitor cells and erythroid progenitor cells. The degree of mobilization appeared to be related to the dose of MGDF. An interesting observation was that the kinetics of progenitor cell release from the marrow were unlike that of other lineage-dominant cytokines, such as G-CSF. Following administration of G-CSF, PBPC levels rose almost immediately, peaked at day 5 or 6 and fell when G-CSF was ceased. However, MGDF resulted in a late and sustained rise in progenitor cells, so that increased levels were first detected only on day 8, after the first dose, and were generally greater on day 12, despite discontinuation of the cytokine several days earlier. TPO has also been found to increase PBPC levels.

Administration of MGDF 0.3 to 5.0 µg/kg combined with filgrastim after chemotherapy significantly enhanced mobilization of PBPC compared with placebo plus filgrastim. Furthermore, higher peak levels of PBPC were observed with increasing doses of MGDF (53).

**Platelet function:** An increased sensitivity of platelets to aggregating agents by TPO has not been observed in clinical studies. There were no significant changes in aggregation response or ATP release between baseline measurements and repeated testing during and after TPO alone (52), or after MGDF when given alone (61) or with filgrastim after chemotherapy (53). Furthermore, there were no changes in coagulation parameters. The platelets produced by MGDF were morphologically normal by light and electron microscopy, and platelet activation markers did not change (61). In addition, in a patient who was given acetylsalicylic acid because of asymptomatic thrombocytosis due to MGDF (platelets peaking at 1876×10⁹/L), platelets responded with the expected inhibition of the aggregation response and ATP release (61).

**Acute toxicity:** Importantly, TPO has been associated with minimal acute toxicity. No constitutional symptoms nor changes in performance status, vital signs, body weight, or biochemical, renal or liver function tests have occurred in studies with MGDF (53,54) or TPO (52). Unlike other, less
potent thrombopoietic cytokines, there was no evidence of induction of an acute phase response. A number of patients have been reported to develop very high platelet counts (greater than $1000 \times 10^9/\text{L}$) without clinical sequelae. There were no significant differences in nonhematological toxicity between the groups who received pegylated recombinant human megakaryocyte growth and development factor compared with placebo. While thromboembolic events have been reported in patients receiving MGDF, the incidence appears to be no greater than that in patients given placebo and is consistent with the expected incidence in patients with advanced malignancy.

The observations of minimal toxicity and the lack of effect on function suggest that platelets produced in response to TPO or MGDF are more similar to normal platelets or those in patients with reactive thrombocytosis, than to the abnormal platelets in patients with a myeloproliferative disorder. In vitro abnormalities of platelet aggregation and clinical hemorrhagic and thrombotic events seldom occur in reactive thrombocytosis, but are quite common in patients with essential thrombocytosis (62,63). In addition, a tendency toward thrombosis, in patients with thrombocytosis, is more closely linked to abnormalities in platelet function than to platelet count (64).

**FUTURE APPLICATIONS**

Early studies with MGDF and TPO suggested that these agents would find a role in a number of clinical situations. The most obvious are those in which severe thrombocytopenia and its consequences are a major cause of morbidity. These include the treatment of acute leukemia, stem cell transplantation, salvage therapy for lymphoma, bone marrow failure states, major surgery, liver disease and immune destruction of platelets. Early reports in acute leukemia and PBPC transplantation are disappointing (57,65); however, these studies did not address the important issues of dose and schedule of a cytokine.

Inadequate TPO production has been shown to be at least partly responsible for the thrombocytopenia associated with cirrhosis (66,67) and interferon treatment of chronic hepatitis C (68). The potent effect of TPO and MGDF on platelet production suggests that these molecules may prevent the complications of thrombocytopenia of chronic liver disease or facilitate the use of interferon in chronic viral hepatitis. However, no clinical reports of the use of TPO for these indications have been presented.

Because of its potency and apparent low level of toxicity, one of the most promising indications for TPO is in the treatment of platelet donors or patients with diseases associated with chronic thrombocytopenia. Use in platelet donors has the potential to enhance the efficiency of platelet collection and reduce the pool of donors required. Early trials of MGDF in platelet donors have been encouraging (69,70), but recent reports of the development of neutralizing antibodies to TPO in patients receiving multiple injections of MGDF (55) have led to the abandonment of the development of this molecule. The appearance of antibodies has also been reported in patients given TPO, but the biological activity of antibodies in these studies is not known (52). These are intriguing observations, and similar incidents have not occurred following administration of other hematopoietic cytokines. The reason for the development of antibodies may partly lie in the long half-life of these molecules, which is approximately 36 h (52). This may set up an antigenic stimulus that results in antibody formation after multiple injections. The discovery of peptide agonists of c-mpl that are as potent as TPO in vitro (71) may pave the way for less immunogenic drugs to be developed.

**CONCLUSIONS**

The discovery of cytokines that stimulate platelet production and provide a means to protect against disease-related and treatment-induced thrombocytopenia is one of great promise. Indeed, the pace of clinical development of these agents is extraordinarily rapid. For instance, IL-11 was recently licensed for the secondary prevention of chemotherapy-induced thrombocytopenia only three years after the initial research application was submitted to the United States Food and Drug Administration. In addition, the clinical formulations of Mpl ligands entered clinical trials only nine months after the papers describing their discovery were published. However, the challenge of finding relevant clinical uses for thrombopoietic cytokines remains an important research priority for the future. The trials that resulted in the approval of IL-11 were ingenious in design but were performed in clinical scenarios for which there are few standard therapeutic equivalents. This is similar to the events that led to the approval of G-CSF, and later resulted in vigorous debate regarding the true value of G-CSF in prevention of neutropenia in standard cancer therapy. Clinical investigators and companies involved in trials of the thrombopoietic cytokines need to develop these valuable agents in a manner that maximizes their clinical value for the short and long term (72).

**REFERENCES**


